Biotech RadarJobs updated

COMPANY

Eilean Therapeutics

HQ: Dover, DE source · eileanther.com ↗

Clinical Phase 1

Keywords: cancer Advanced Solid Tumor Cancer Type 2 Diabetes Polycythemia Vera Myelofibrosis ZE66-0205 ZE94-0605 ZE63-0302 ZE74-0282

Location: Dover, DE · source · Oct 13, 2026

Profile checked Oct 10, 2026

5Trials (company is sponsor)

Timeline

  1. Trial start Phase 1: A First-in-Human Study of ZE66-0205 in Healthy Volunteers source ↗
  2. Trial start Phase 1: A First-in-Human Study of ZE94-0605 in Patients With Advanced Solid Tumors source ↗
  3. Trial start Phase 1: Study of ZE74-0282 for Patients With JAK2 V617F Positive Blood Cancers source ↗
  4. Trial start Phase 1: Study to Assess Safety, Tolerability, PK, and PD of Multiple Doses of ZE63-0302 Administrated Orally in T2DM Patients. source ↗
  5. Trial start Phase 1: Сlinical Study Aiming to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses of ZE63-0302 in Healthy Volunteers source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 5

RecordTitlePhaseStatusStartPrimary completion
NCT07735728A First-in-Human Study of ZE66-0205 in Healthy VolunteersPhase 1Not yet recruitingAug 15, 2026Aug 15, 2027 (estimated)
NCT07524140A First-in-Human Study of ZE94-0605 in Patients With Advanced Solid TumorsPhase 1RecruitingJun 25, 20262028-01 (estimated)
NCT07234864Study to Assess Safety, Tolerability, PK, and PD of Multiple Doses of ZE63-0302 Administrated Orally in T2DM Patients.Phase 1Active, not recruitingNov 19, 2025Apr 21, 2026 (actual)
NCT07529951Study of ZE74-0282 for Patients With JAK2 V617F Positive Blood CancersPhase 1Not yet recruitingMay 15, 2026Sep 30, 2028 (estimated)
NCT06780124Сlinical Study Aiming to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses of ZE63-0302 in Healthy VolunteersPhase 1CompletedApr 12, 2024Jun 24, 2025 (actual)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

Feedback